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ABSTRACT
Objective: identify the main adverse reactions presented by patients with HER2 positive breast cancer 
from an outpatient clinic specialized in chemotherapy in the city of Caruaru-PE, after the use of Trastu-
zumab.
Methods: The data were obtained through the analysis of the medical records of the patients attended at 
the outpatient clinic from January 2015 to December 2016. 
Results: Twenty-four patients were selected, of whom 12.5%  presented cardiotoxicity and 4.16% pre-
sented abdominal pain, nausea among other adverse events.
Conclusion: Identifying such adverse events makes it possible to better assist the oncological patient 
and to better adhesion to the treatment. Because they are specific target drugs, few studies are concerned 
with evaluating these adverse events, which often makes clinical care difficult.
Keywords: Antibodies, Monoclonal, Breast Neoplasms, Trastuzumab, Drug-Related Side Effects and 
Adverse Reactions, Medical Oncology.
RESUMEN
Objetivo: identificar las principales reacciones adversas presentadas por pacientes con cáncer de mama 
HER2 positivo desde una clínica ambulatoria especializada en quimioterapia en la ciudad de Caruaru-
PE (Brasil), después del uso de Trastuzumab. 
Métodos: los datos se obtuvieron mediante el análisis de los registros médicos de los pacientes atendidos 
en la consulta externa entre enero de 2015 y diciembre de 2016.
Resultados: se seleccionaron 24 pacientes, de los cuales 12.5% presentaron cardiotoxicidad y 4.16% pre-
sentaron dolor abdominal, náuseas entre otros eventos adversos.
Conclusión: la identificación de tales eventos adversos permite una mejor asistencia al paciente on-
cológico y una mejor adhesión al tratamiento. Debido a que son medicamentos específicos, pocos es-
tudios se preocupan por evaluar estos efectos adversos, lo que a menudo dificulta la atención clínica.
Palabras clave: Anticuerpos Monoclonales, Neoplasias de la Mama, Trastuzumab, Efectos Colaterales y 
Reacciones Adversas Relacionados a Medicamentos, Oncología Médica.
INTRODUCTION
Antineoplastic chemotherapy consists of the use of cytotoxic drugs alone or in combination, 
which act on tumor cells. In order to inhibit the proliferation of cancer cells, the cell cycle is 
one of the main foci in the action of antineoplastic agents. Each drug class will act at a par-
ticular stage of the cell cycle, not only acting on cancer cells, but also on normal cells of rapid 
proliferation. Therefore, these drugs produce undesirable side effects and are toxic to those 
taking such medications (1).
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Immunotherapy presents as the great proposal of treatment 
of some neoplasias with a focus on the decrease of adverse 
reactions. Tumor immunotherapy is based on the use of 
elements of the immune system to eliminate or neutralize 
tumor cells and factors that benefit tumor survival (2).
Monoclonal antibodies, as target therapy, have high speci-
ficity with few side effects, being the focus of many research 
on diseases that require more aggressive treatment. These 
agents are gaining space in the treatment of some types of 
cancer, as is the case of Trastuzumab in the treatment of 
breast cancer, Cetuximab in the treatment of colorectal can-
cer and Rituximab in the treatment of lymphomas (3).
There are few studies that are concerned with the toxicity 
of monoclonal antibodies in the treatment of malignancies. 
Therefore, this article aims to identify the main adverse re-
actions presented by patients in an outpatient clinic special-
ized in chemotherapy in the city of Caruaru-PE.
MATERIAL AND METHODS
This is a retrospective, quantitative and descriptive study 
based on the medical records of patients who used the 
monoclonal antibody Trastuzumab. Data collection took 
place from February to June 2017, in which the medical re-
cords of the patients of the Caruaru Oncology Center, who 
used the Trastuzumab antibody, were evaluated as isolated 
therapy or associated with other chemotherapeutic agents 
for the treatment of breast cancer HER2 positive.
A total of 59 patients attended at the outpatient clinic from 
January 2015 to December 2016, who used the monoclonal 
antibody Trastuzumab, associated or not with other anti-
neoplastic agents, were excluded only patients who under-
went hormone therapy, since hormone therapy alone, may 
be object of study in specific work, not being included in 
the objectives of this work. The analysis of medical records 
sought data such as: patient identification, cancer classifi-
cation, drugs used to treat cancer, time of chemotherapy 
treatment, presence of associated diseases, laboratory and 
imaging exams, using as an aid an adapted data collection 
tool of the Instrument for Data Collection of the Oswaldo 
Cruz Foundation's Report of 2014.
The inclusion criteria used were female patients with 
HER2-positive breast cancer who used Trastuzumab in the 
treatment of their neoplasia, whether or not they were as-
sociated with other antineoplastic agents. The established 
exclusion criteria were patients with other types of cancer 
that did not express the HER2 receptor, as well as smokers 
and patients who underwent antiestrogen therapy.
After the retrospective analysis of the medical records, it 
was verified that of the 59 patients selected, only 24 met the 
established criteria.
RESULTS
The study consisted of 24 female patients with HER2 posi-
tive breast cancer, in whom the analysis of the data collected 
revealed that the patients' age ranged from 35 to 71 years. 
It was verified that about 6 patients had hypertension and 
2 had diabetes. Regarding the histological classification of 
cancer, 21 patients presented Ductal Invasive Carcinoma, 
Figure 1 shows the main histological types presented by the 
patients.
FIGURE 1 - Prevalence of the histological type of breast 
cancer in the patients analyzed in this study
Analyzing the clinical staging of these patients, it was ob-
served that of the 24 patients, 13 had stage III, 4 stage IIB, 3 
stage IIA, 2 stage II and 2 stage I, which shows a predomi-
nance of patients in stage III, in the sample there were no 
patients in stage IV.
Regarding the therapeutic approach, about 8 patients un-
derwent a surgical procedure, of which 6 performed Radi-
cal Mastectomy and 2 underwent Quadrantectomy with 
axillary emptying. Regarding radiotherapy, 19 patients 
performed, of which 10 did before starting treatment with 
Trastuzumab and 9 discontinued the use of Trastuzumab 
for radiotherapy and returned to the administration of 
Trastuzumab after radiotherapy, in which the mean dosage 
was 50.4 Gray.
FIGURE 2 - Prevalence of patients with initial therapeutic 
approach with anthracyclines
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 As for chemotherapy, the vast majority of patients had pro-
tocols with anthracyclines, as shown in Figure 2, in which 
the protocol Doxorubicin associated with Cyclophospha-
mide was one of the most used by the study patients. 
After treatment with anthracycline protocols, 16 patients 
performed protocols with taxanes associated or not with 
Trastuzumab, of which 10 used Paclitaxel and 6 who used 
Docetaxel.
During the administration of the doses of Trastuzumab, 
three patients discontinued the use of the monoclonal anti-
body due to a decrease in the ejection fraction after the 6th, 
7th and 10th cycles, one presented pulmonary thromboem-
bolism after the 6th cycle, another presented dysuria after 
the 7th cycle, another patient had a seizure after the 12th cy-
cle of Trastuzumab, in which an magnetic resonance imag-
ing was performed on the skull showing the possibility of 
metastasis. Another reported constipation after the second 
cycle, abdominal pain after the 7th cycle and nausea after 
the 9th cycle and another patient presented odynophagia 
after the 5th cycle of Trastuzumab.
DISCUSSION
Chemotherapy is based on the application of non-specific 
antineoplastic agents, injuring both normal and malig-
nant cells, inhibiting the growth and / or vital processes 
of tumor cells (4). Currently, one of the major stakes in the 
treatment of cancer is immunotherapy, which consists of 
stimulation of the immune system through the use of sub-
stances modifying the biological response, which may oc-
cur through the result of the antigen-antibody interaction 
or the mechanisms involved in the mediated immunity by 
cells (5).
Monoclonal antibodies are products based on modified im-
munoglobulins, which exert a specific effect on a specific 
target, which makes it one of the great bets in the treatment 
of certain tumors, as it decreases the adverse reactions 
caused by the antineoplastic chemotherapeutics. The main 
antibodies used in the clinic are Cetuximab, Rituximab, 
Trastuzumab, Bevacizumab, among others (6).
Trastuzumab is a humanized monoclonal antibody that 
acts on human epidermal growth factor receptor-2 (HER2), 
in which its target is the subdomain IV of the extracellular 
region of HER2, being indicated in the treatment of breast 
cancer with high expression of HER2 and in the treatment 
of adenocarcinoma of the gastroesophageal or metastatic 
gastric junction with high expression of HER2. Its mecha-
nism of action is associated with interference with signal 
transduction pathways, inhibition of extracellular domain 
cleavage, inhibition of DNA repair, reduction of angiogen-
esis, induction of cell cycle arrest, activation of antibody-
dependent cellular cytotoxicity (6).
According to the study by Cintra et al (7), the age range of 
patients with breast cancer with HER2 overexpression pre-
sents in two peaks 40 and 59 years and 70 years or older, 
which is consistent with the data collected in the study, also 
demonstrating the predominance of invasive ductal histo-
logical type with 73.3% of the cases. With respect to clinical 
staging, Santos et al (8) demonstrated a greater number of 
patients with stage III and II, corroborating the data col-
lected in this study, presenting 13 patients in stage III and 9 
patients with stage II as shown in Figure 3.
FIGURE 3 - Clinical staging of study patients 
These are new drugs in the clinic, for this reason, there 
is very little information on its side effects, although its 
mechanisms of action are very specific, these monoclonal 
antibodies are not free of side effects. Trastuzumab is often 
associated with significant cardiotoxicity, which is primar-
ily responsible for premature termination of treatment, in 
which this effect may be related to arterial hypertension, 
age greater than 50 years, exposure to anthracyclines (Dox-
orubicin, Epirubicin and Daunorubicin) and baseline left 
ventricular ejection fraction (9).
According to the study by Ayres et al (10), about 32.9% of 
patients using Trastuzumab have cardiotoxicity. Other ad-
verse events also seen in chemotherapy combined with 
Trastuzumab include pain (myalgia / arthralgia) (20.4%), 
nausea and vomiting (15.9%), fever (9.7%) and neutropenia 
(7.1%), with respect to the use of Trastuzumab monother-
apy, the most frequent adverse events were pain (19.6%), 
fatigue (10.8%), nausea and vomiting (9.8%) and headache 
(8.8%). Table 1 presents the main adverse events presented 
by the study patients, presenting results with some reac-
tions different from those presented in the Ayres et al (10) 
study.
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TABLE 1 - Main adverse events found by the use of  
Trastuzumab
Adverse event
Number of 
patients
Frequency
Cardiotoxicity 3 12,5%
Pulmonary thromboembolism 1 4,16%
Dysuria 1 4,16%
Constipation 1 4,16%
Abdominal pain 1 4,16%
Nausea 1 4,16%
Odynophagia 1 4,16%
Some clinical studies have demonstrated that Trastuzumab 
can cause damage to the myocardium, with a reduction in 
the contractile force of the left ventricle, and it is possible 
to reverse this clinical situation after the suspension of the 
drug since there is no damage to the cardiomyocyte. Be-
tween 3.5% and 17.3% of patients using trastuzumab as-
sociated with chemotherapy, there is a reduction in asymp-
tomatic ejection fraction and from 2.5% to 5.1% have severe 
myocardial failure (11).
One of the most used tests in the clinic for the cardiac eval-
uation of these patients is the echocardiogram because it 
allows to evaluate not only the systolic function but also 
the diastolic function, the cardiac valves and the pericar-
dium. The examination is performed periodically follow-
ing the cycles of chemotherapy with this aiming to detect 
early myocardial lesion, in which the initial attention is at-
tributed to the systolic function, with the calculation of the 
ejection fraction, the shortening function, the cavity dimen-
sions and ventricular volumes (11).
According to the National Institutes of Health (NIH), the 
definition of cardiotoxicity in oncology in the last two dec-
ades is based on measurements of left ventricular ejection 
fraction (LVEF), defined as Grade I (asymptomatic LVEF 
reduction between 10% and 20%), Grade II (reduction of 
LVEF below 20% or below normal) and Grade III (sympto-
matic heart failure) (12). The three patients who discontinued 
use of Trastuzumab were due to drop in ejection fraction by 
more than 20%, indicating cardiotoxicity.
CONCLUSION
The analysis of the results of this retrospective study of 
the medical records of patients with HER2 positive breast 
cancer and the adverse reactions to the treatment with the 
monoclonal antibody Trastuzumab, concludes that the 
monitoring and notification of these adverse events, as well 
as the need for cardiological follow-up of these patients is 
of fundamental importance with a focus on the reduction 
of risks and the benefit of therapeutics. Because they are 
specific target drugs, few studies are concerned with evalu-
ating the possible adverse events caused by these agents, 
often correlating with other clinical situations of cancer pa-
tients. Based on data found in the research, a need to com-
bine efforts among efforts among oncologists, cardiologists, 
nurses and clinical pharmacists was recognized, in order to 
identify these adverse events.
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